EstechPharma Co. Ltd (041910) - Net Assets
Based on the latest financial reports, EstechPharma Co. Ltd (041910) has net assets worth ₩135.93 Billion KRW (≈ $92.12 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩195.93 Billion ≈ $132.78 Million USD) and total liabilities (₩60.00 Billion ≈ $40.66 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are EstechPharma Co. Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩135.93 Billion |
| % of Total Assets | 69.38% |
| Annual Growth Rate | 5.95% |
| 5-Year Change | 10.24% |
| 10-Year Change | 75.56% |
| Growth Volatility | 6.34 |
EstechPharma Co. Ltd - Net Assets Trend (2013–2025)
This chart illustrates how EstechPharma Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore EstechPharma Co. Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for EstechPharma Co. Ltd (2013–2025)
The table below shows the annual net assets of EstechPharma Co. Ltd from 2013 to 2025. For live valuation and market cap data, see EstechPharma Co. Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩135.93 Billion ≈ $92.12 Million |
+5.71% |
| 2024-12-31 | ₩128.58 Billion ≈ $87.14 Million |
+11.20% |
| 2023-12-31 | ₩115.63 Billion ≈ $78.36 Million |
-0.39% |
| 2022-12-31 | ₩116.09 Billion ≈ $78.67 Million |
-5.85% |
| 2021-12-31 | ₩123.30 Billion ≈ $83.56 Million |
+10.69% |
| 2020-12-31 | ₩111.39 Billion ≈ $75.49 Million |
+8.44% |
| 2019-12-31 | ₩102.72 Billion ≈ $69.61 Million |
+15.09% |
| 2018-12-31 | ₩89.25 Billion ≈ $60.48 Million |
+8.34% |
| 2017-12-31 | ₩82.38 Billion ≈ $55.83 Million |
+6.41% |
| 2016-12-31 | ₩77.42 Billion ≈ $52.47 Million |
+7.34% |
| 2015-12-31 | ₩72.13 Billion ≈ $48.88 Million |
-5.08% |
| 2014-12-31 | ₩75.99 Billion ≈ $51.50 Million |
+11.81% |
| 2013-12-31 | ₩67.96 Billion ≈ $46.05 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to EstechPharma Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 9226463860000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩92.26 Billion | 67.88% |
| Other Components | ₩43.66 Billion | 32.12% |
| Total Equity | ₩135.93 Billion | 100.00% |
EstechPharma Co. Ltd Competitors by Market Cap
The table below lists competitors of EstechPharma Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Newfield Resources Ltd
AU:NWF
|
$59.24 Million |
|
SERESCO (ACC.P.DESD.)-16
F:XV7
|
$59.25 Million |
|
iLearningEngines, Inc.
NASDAQ:AILE
|
$59.29 Million |
|
Manba Finance Ltd
NSE:MANBA
|
$59.30 Million |
|
YES24 Co.Ltd
KQ:053280
|
$59.18 Million |
|
Vishnu Prakash R Punglia Limited
NSE:VPRPL
|
$59.18 Million |
|
Korea Steel Co Ltd
KO:007280
|
$59.17 Million |
|
Telcoware
KO:078000
|
$59.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EstechPharma Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 128,582,659,930 to 135,927,147,010, a change of 7,344,487,080 (5.7%).
- Net income of 6,160,941,850 contributed positively to equity growth.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩6.16 Billion | +4.53% |
| Other Changes | ₩1.18 Billion | +0.87% |
| Total Change | ₩- | 5.71% |
Book Value vs Market Value Analysis
This analysis compares EstechPharma Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.73x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.09x to 0.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩6860.74 | ₩7480.00 | x |
| 2017-12-31 | ₩7127.86 | ₩7480.00 | x |
| 2018-12-31 | ₩7641.34 | ₩7480.00 | x |
| 2019-12-31 | ₩8794.54 | ₩7480.00 | x |
| 2020-12-31 | ₩9537.09 | ₩7480.00 | x |
| 2021-12-31 | ₩10556.39 | ₩7480.00 | x |
| 2022-12-31 | ₩9939.13 | ₩7480.00 | x |
| 2023-12-31 | ₩9900.05 | ₩7480.00 | x |
| 2024-12-31 | ₩9679.99 | ₩7480.00 | x |
| 2025-12-31 | ₩10232.90 | ₩7480.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EstechPharma Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.09%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.44x
- Recent ROE (4.53%) is below the historical average (5.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 5.45% | 8.76% | 0.40x | 1.54x | ₩-3.09 Billion |
| 2014 | 11.24% | 19.31% | 0.39x | 1.51x | ₩940.02 Million |
| 2015 | -1.21% | -1.93% | 0.49x | 1.27x | ₩-8.08 Billion |
| 2016 | 5.36% | 9.56% | 0.45x | 1.26x | ₩-3.59 Billion |
| 2017 | 3.31% | 7.13% | 0.40x | 1.15x | ₩-5.51 Billion |
| 2018 | 7.38% | 16.34% | 0.41x | 1.10x | ₩-2.34 Billion |
| 2019 | 14.82% | 32.76% | 0.40x | 1.13x | ₩4.96 Billion |
| 2020 | 9.84% | 17.87% | 0.50x | 1.11x | ₩-182.46 Million |
| 2021 | 5.58% | 11.38% | 0.45x | 1.09x | ₩-5.46 Billion |
| 2022 | -5.48% | -10.26% | 0.50x | 1.07x | ₩-17.97 Billion |
| 2023 | 3.31% | 5.95% | 0.53x | 1.05x | ₩-7.74 Billion |
| 2024 | 3.07% | 6.62% | 0.44x | 1.05x | ₩-8.91 Billion |
| 2025 | 4.53% | 11.09% | 0.28x | 1.44x | ₩-7.43 Billion |
Industry Comparison
This section compares EstechPharma Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $71,975,119,751
- Average return on equity (ROE) among peers: -0.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EstechPharma Co. Ltd (041910) | ₩135.93 Billion | 5.45% | 0.44x | $59.21 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $86.63 Billion | 1.55% | 0.41x | $6.03 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $102.11 Billion | 6.48% | 0.69x | $33.52 Million |
| NatureCell Co.Ltd (007390) | $-16.60 Million | 0.00% | 0.00x | $688.81 Million |
| Sam-A Pharm. Co. Ltd (009300) | $79.92 Billion | 4.39% | 0.39x | $68.66 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $150.62 Billion | 13.47% | 0.23x | $89.89 Million |
| WooGene B&G Co. Ltd (018620) | $22.14 Billion | 0.79% | 1.63x | $13.13 Million |
| Oscotec Inc (039200) | $94.72 Billion | -25.63% | 0.40x | $990.30 Million |
| Komipharm International Co. Ltd (041960) | $76.13 Billion | -8.60% | 0.75x | $380.81 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $35.53 Billion | 3.47% | 0.29x | $34.35 Million |
About EstechPharma Co. Ltd
EstechPharma Co., Ltd. manufactures and sells pharmaceuticals products. It also offers raw materials, such as RBM and PLK. The company was formerly known as Estech Chemical and changed its name to EstechPharma Co., Ltd. in January 2001. EstechPharma Co., Ltd. was founded in 1996 and is headquartered in Hwaseong-si, South Korea.